Walgreens told a Texas Medicare patient his new COPD nebulizer drug was delayed over an insurance issue, but after his death his widow was left with conflicting explanations about whether prior authorization, Medicare Part B billing, or a missing diagnostic code held up the prescription. The case underscores how administrative confusion around Medicare drug coverage can delay clinician-ordered treatment for severe flare-ups and leave bedside teams unsure who must act next.

The Move

• On June 2, Kenney Blewett’s pulmonologist prescribed a liquid COPD medication to be inhaled by nebulizer to ease worsening breathing flare-ups.

• Two days later, Walgreens emailed that the prescription was delayed because of an insurance issue.

• Blewett’s wife said pharmacy staff initially described the problem as prior authorization, but later a Walgreens supervisor said the claim had been submitted to Medicare Part B and was missing a diagnostic code from the physician.

• Medicare told the family it had no record the prescription had been billed to Part B, and the pulmonology practice said it did not see a fax requesting the code.

Why It Matters for Care

• For clinicians, the practical issue is that nebulized COPD drugs may be covered under Medicare Part B’s durable medical equipment benefit rather than Part D, creating a high-risk handoff between prescriber, pharmacy, and payer.

• When coverage pathways are unclear, patients with advanced Disorder of lung can face delays in starting symptom-relieving therapy during periods of escalating dyspnea.

• At the bedside, staff may need to verify in real time which Medicare benefit applies, whether a diagnosis code is required on the prescription, and who is responsible for follow-up with the dispensing pharmacy.

• The family linked the delay to a period of severe distress before Blewett died by suicide, underscoring how access barriers can compound suffering in medically and psychiatrically vulnerable patients.

Between the Lines

• This is less a single denial story than a fragmentation story: traditional Medicare, private Part D coverage, Medigap, pharmacy workflow, and specialist office processes all intersected without a clear accountable owner.

• That complexity persists despite a Trump administration-backed voluntary insurer pledge to ease prior authorization, because the pledge lacks enforcement and does not resolve Medicare benefit-design confusion.

• State lawmakers have tried to regulate prior authorization, but many plans covering older adults, including traditional Medicare and many employer plans, sit outside state reach.

• Clinicians and advocates warn that CMS testing of AI-assisted prior authorization in Original Medicare could add more administrative friction even if COPD drugs are not yet included.

What to Watch

• Whether CMS expands its six-state Original Medicare prior authorization pilot beyond current services or into additional states.

• Whether federal regulators issue clearer operational guidance on Part B versus Part D handling for nebulized respiratory drugs.

• Whether Congress or the administration moves from voluntary insurer commitments to enforceable prior authorization standards.

• Whether pharmacies, EHR vendors, and specialty practices adopt tighter coding and claim-routing workflows to prevent similar delays.

Source: KFF Health News